The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID‐19 infection

• Published in: The FEBS journal Vol. 288; no. 17; pp. 5179 - 5189
• Main Authors: Merzon, Eugene, Green, Ilan, Vinker, Shlomo, Golan‐Cohen, Avivit, Gorohovski, Alessandro, Avramovich, Eva, Frenkel‐Morgenstern, Milana, Magen, Eli
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2021; John Wiley and Sons Inc
• Subjects: Acetylsalicylic acid; Aspirin; Cardiovascular disease; Cardiovascular diseases; Chronic obstructive pulmonary disease; COVID-19; COVID-19 infection; cross-sectional studies; diabetes; Diabetes mellitus; Disease control; disease likelihood; Disease prevention; Hypertension; Infections; Israeli cohort; mortality; Original; Population studies; protective effect; Viral diseases; COVID-19; Israeli cohort; aspirin; disease likelihood

Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID‐19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective...